{"id":6605,"date":"2022-02-24T18:07:46","date_gmt":"2022-02-24T17:07:46","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=6605"},"modified":"2022-02-24T18:10:02","modified_gmt":"2022-02-24T17:10:02","slug":"ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/","title":{"rendered":"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&rsquo;enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3 class=\"Default\">24\/02\/2022 \u2013 AB Science annonce qu\u2019elle tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&rsquo;enregistrement du masitinib dans le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA) au Canada sous la proc\u00e9dure NOC\/c, ainsi que sur son programme clinique dans toutes les indications<\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMi8wMi9XZWJjYXN0LTI4LUZlYnJ1YXJ5LTIwMjItVkZSLVZGLnBkZiZzZXR0aW5ncz0xMTEwMTExMTExMTExMTExMTAwJmxhbmc9ZW4tVVM=#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-e0ad74ef704cc67ac2a8b7cfde6a4ae8.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-e0ad74ef704cc67ac2a8b7cfde6a4ae8 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2022\/02\/Webcast-28-February-2022-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1645722324230\" target=\"_blank\" id=\"default-btn-e0ad74ef704cc67ac2a8b7cfde6a4ae8\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] 24\/02\/2022 \u2013 AB Science annonce qu\u2019elle tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&rsquo;enregistrement du masitinib dans le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA) au Canada sous la proc\u00e9dure NOC\/c, ainsi que sur son programme clinique dans toutes les indications [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[117,121,93,116],"class_list":["post-6605","post","type-post","status-publish","format-standard","hentry","category-2022-fr","tag-ab10015","tag-als-fr","tag-masitinib-fr","tag-riluzole","category-127","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&#039;enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&#039;enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-24T17:07:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-24T17:10:02+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&rsquo;enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications\",\"datePublished\":\"2022-02-24T17:07:46+00:00\",\"dateModified\":\"2022-02-24T17:10:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/\"},\"wordCount\":183,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"keywords\":[\"AB10015\",\"ALS\",\"Masitinib\",\"riluzole\"],\"articleSection\":[\"2022\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/\",\"name\":\"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d'enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-02-24T17:07:46+00:00\",\"dateModified\":\"2022-02-24T17:10:02+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&rsquo;enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d'enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d'enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/","og_site_name":"AB Science","article_published_time":"2022-02-24T17:07:46+00:00","article_modified_time":"2022-02-24T17:10:02+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&rsquo;enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications","datePublished":"2022-02-24T17:07:46+00:00","dateModified":"2022-02-24T17:10:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/"},"wordCount":183,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"keywords":["AB10015","ALS","Masitinib","riluzole"],"articleSection":["2022"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/","name":"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d'enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2022-02-24T17:07:46+00:00","dateModified":"2022-02-24T17:10:02+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science tiendra une conf\u00e9rence virtuelle le 28 f\u00e9vrier 2022 sur la demande d&rsquo;enregistrement du masitinib dans le traitement SLA au Canada, ainsi que sur son programme clinique dans toutes les indications"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/6605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=6605"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/6605\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=6605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=6605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=6605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}